Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences
Go back to Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences| (NASDAQ: EDIT) | Delayed: 2.80 +0.11 (4.09%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.69 | 52 Week High | $43.99 | |||
| Open | $2.70 | 52 Week Low | $12.43 | |||
| Day High | $2.88 | P/E | N/A | |||
| Day Low | $2.69 | EPS | $0.00 | |||
| Volume | 2,919,003 | |||||
